AYER, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- AMSC® (NASDAQ: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™ and protect and expand the capability of our Navy’s fleet, announced today that it plans to release its first quarter fiscal year 2025 financial results after the market close on Wednesday, July 30, 2025. In conjunction with this announcement, AMSC management will participate in a conference call with investo ...

Core Viewpoint - Abaxx Technologies Inc. has launched its physically-deliverable Gold Singapore Futures, which began active trading on June 12, 2025, providing a new tool for price discovery and hedging in the Asian market [1][3]. Company Overview - Abaxx Technologies is a financial software and market infrastructure company, and the majority shareholder of Abaxx Singapore Pte Ltd., which owns the Abaxx Commodity Exchange and Clearinghouse [1][7]. - The company aims to create Smarter Markets by developing better tools and technology to address significant societal challenges, including the energy transition [6]. Product Details - The Gold Singapore Futures contract is a USD-denominated, kilobar-sized product designed for the regional physical bullion trade, deliverable into approved vaults in Singapore [2][3]. - This contract is tailored for refiners, industrial consumers, banks, and physical traders in Asia, addressing the growing demand for regional price transparency [3][5]. Market Participation - The initial trading sessions of the Gold Singapore Futures saw participation from eight market makers, including firms from Singapore, Hong Kong, London, and Thailand, with expectations for more participants in the future [4]. - KGI Securities Singapore expressed enthusiasm for the new offering, highlighting its relevance to the Asian market and commitment to providing comprehensive solutions in commodities [5]. Trading Specifications - The Abaxx Gold Singapore Futures contract is available for trading 14 hours per day, Monday through Friday, facilitating access for market participants [5].

Core Insights - Abaxx Technologies Inc. has launched a physically-deliverable Gold Kilobar Futures contract and a new gold trading platform, Abaxx Spot, in Singapore, aiming to enhance market infrastructure for precious metals [1][2][3] Company Overview - Abaxx Technologies is a financial software and market infrastructure company, and the majority shareholder of Abaxx Singapore Pte. Ltd., which owns the Abaxx Commodity Futures Exchange and Clearinghouse [1][10] - The company focuses on building smarter markets through better tools, benchmarks, and technology to address societal challenges, including the energy transition [10] Product Launch - The Gold Kilobar Futures contract is USD-denominated, physically deliverable, and sized to 1-kilogram, 9999-purity bars, catering to Asia's bullion trade [3][6] - Abaxx Spot provides a secure platform for the transfer of physically-allocated gold, allowing registered participants to maintain title to an undivided interest in the gold held in appointed vaults [5][7] Market Impact - This launch represents the first co-located spot and futures infrastructure for gold, designed to reduce fragmentation in global gold markets and align trading practices with actual market operations [2][6] - The integrated infrastructure aims to address structural inefficiencies that separate global benchmarks from physical trade, with pricing traditionally anchored in New York and London [8][12] Trading Operations - Trading on the Abaxx Gold Singapore Futures contract is available 14 hours per day, Monday through Friday, providing a regionally anchored benchmark for price discovery and risk management [4][3] - The platform is designed for physical market participants, including bullion dealers and refiners, offering global access to kilobar gold trading without the complexities of traditional OTC markets [7][8]

Financial Data and Key Metrics Changes - For Q2 of fiscal 2025, total revenue was $124.3 million, a 4.4% increase from $119 million in Q2 of fiscal 2024, primarily driven by an increase in RMS segment revenue [8][25] - Adjusted EBITDA for Q2 was $8 million, or 6.4% of total revenue, compared to $3.1 million, or 2.6% of total revenue in the same quarter last year [27][28] - Consolidated net loss attributable to common shareholders was $14.9 million, or a loss of $0.44 per diluted share, compared to a loss of $48.1 million, or $1.86 per diluted share in Q2 of fiscal 2024 [27] Business Line Data and Key Metrics Changes - RMS segment revenue increased by $6.6 million, or 9.1%, compared to Q2 of fiscal 2024, mainly due to higher NHP volumes sold [25][26] - DSA revenue decreased to $45.3 million from $46.6 million in Q2 of fiscal 2024, primarily due to a decline in general toxicology services revenue [26] - DSA net new orders were $44.5 million, a 27% increase over Q2 of fiscal 2024, with a book to bill ratio of 1.01:1 [26][28] Market Data and Key Metrics Changes - The company noted geopolitical and macroeconomic risks affecting the industry, but expects continued year-over-year revenue and adjusted EBITDA growth for the next two quarters [9][23] - The company has not seen material changes in demand due to current tariffs, although there is some cost inflation linked to tariffs [22][23] Company Strategy and Development Direction - The company is focused on client satisfaction, integration of scientific services, and site optimization plans to improve operational efficiency and margins [7][10] - A revised RMS site optimization plan is expected to yield annual cost savings of $6 million to $7 million, with completion anticipated by March 2026 [11][12] - The company is adapting to FDA announcements regarding drug development and animal testing, positioning itself to leverage new methodologies [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the level of quoting and awards in the DSA segment, expecting improvements in margins starting in Q3 of fiscal 2025 [49][86] - The company is monitoring NIH funding impacts but has not seen significant changes in business yet [52][54] - Management remains confident in the company's ability to navigate geopolitical and macroeconomic uncertainties while creating value for clients and shareholders [23][24] Other Important Information - The company plans to hold an Investor Day on May 29 to further discuss its strategic plan and focus on client excellence [87] - The company has made significant investments in acquisitions and site optimizations to prepare for future growth [7][10] Q&A Session Summary Question: Changes in marketing strategies post-FDA announcement - Management has integrated new services into their discovery sales process and is seeing some growth, though not as rapid as expected [35][36] Question: Focus areas in the revised RMS optimization plan - The revised plan aims to improve efficiencies and reduce costs, with a focus on maximizing existing resources rather than expanding capacity [40][41] Question: Current demand trends and quoting activity - Management reported a positive start to the current quarter, with strong quoting and closing activity [46][49] Question: Impact of NIH funding on customer mix - There has been no dramatic impact from NIH funding yet, with some customers increasing orders while others have reduced them [52][54] Question: DSA margin improvement timeline - Management expects to see benefits from identified margin improvement areas sooner rather than later, with some improvements already noted [66][68]

RT MiCA Crypto Alliance (@MiCA_Alliance)We’re pleased to welcome @UKCBT_org as a technical partner of the MiCA Crypto Alliance.UK CBT joins at a key moment for digital asset regulation. On 29 April, @hmtreasury published its near-final crypto framework, setting out new rules for trading platforms, custody, stablecoin issuance, and staking.This partnership will focus on:✅ Expand access to MiCA-aligned policy education and technical insights✅ Support the development of compliance tools✅ Encouraging dialogue a ...